WILEX AG secures further financing with shareholder loan based on an existing financing commitment
Disclosure of an inside information according to Article 17 MAR
Munich, Germany, 11 October 2016 – WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) today signed a subordinated loan agreement for a total amount of up to EUR 3.7 million with its main shareholder dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany (dievini). The amount of the loan corresponds to the remaining amount of the financing commitment from November 2015 of up to EUR 10 million that will secure the company’s cash reach into the second quarter of 2017. The other part of the commitment (EUR 6.3 million) was invested in the company through capital increases in December 2015 and April 2016.
The loan does not have an expiration date, is unsecured and has an interest rate of 6% per annum. WILEX AG may access the loan when needed. The lender is entitled to terminate the loan agreement upon certain conditions; the loan would then become due within one month. In lieu of repayment of the loan in cash, dievini may request repayment by way of a contribution in kind in a capital increase.
+++ End of release +++
WILEX AG is a biopharmaceutical company based in Munich, Germany, that serves as a parent and holding company for the Group. Research and development focus on the operations of its subsidiary Heidelberg Pharma GmbH in Ladenburg, which primarily advances the development of the innovative ADC platform technology based on the compound Amanitin (ATAC technology) and provides preclinical drug research and development services. WILEX has diagnostic and therapeutic Phase-III drug candidates, which are available for out-licensing to external partners. WILEX AG is listed at the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at http://www.wilex.com/.
Tel.: +49 (0)89-41 31 38-29
Grillparzerstr. 18, 81675 Munich
MC Services AG
Katja Arnold (CIRO)
Executive Director & Partner
Tel.: +49-89-210 228-40
Mobile: +49 160 9360 3022
This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.